Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | BRD4 | O60885 | 2/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923298 | 0.87 | CRBN (1.00) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| SCHEMBL17169744 | 0.87 | CRBN (1.00) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| Hydrochloric Acid SCHEMBL19359358 | 0.86 | CRBN (0.97) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| SCHEMBL27053430 | 0.81 | CRBN (0.52) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| SCHEMBL25834137 | 0.81 | CRBN (0.74) | CRBNALDH1A1DDB1IKZF3 | |
| SCHEMBL26765787 | 0.79 | CRBN (0.56) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| SCHEMBL25123978 | 0.76 | CRBN (0.64) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| SCHEMBL26500910 | 0.76 | CRBN (0.77) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| SCHEMBL29332928 | 0.75 | CRBN (0.63) | CRBNALDH1A1KDM4EBRD4DDB1 | |
| SCHEMBL26008657 | 0.75 | ALDH1A1 (1.00) | CRBNALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CRBN 2/4885ALDH1A1 4309/4885KDM4E 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.